Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction

a technology of cd2/lfa3 and skin conditions, which is applied in the direction of antibody medical ingredients, instruments, peptide/protein ingredients, etc., can solve the problems of inadequate current therapies for the above mentioned skin diseases, and achieve the effects of less immunosuppression, less general toxicity, and increased t cell activation and abnormal antigen presentation

Inactive Publication Date: 2006-04-20
ASTELLAS US
View PDF18 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a method for preventing or treating skin conditions by administering an inhibitor of the CD2 / LFA-3 interaction to a mammal. This method is superior to previous therapies as it results in less immunosuppression and more specific therapy with less general toxicity. The invention can be used for a variety of skin conditions, including psoriasis, UV damage, atopic dermatitis, cutaneous T cell lymphoma, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria. The inhibitor can be any molecule that inhibits the CD2 / LFA-3 interaction, such as anti-LFA-3 antibody homologs, anti-CD2 antibody homologs, soluble LFA-3 polypeptides, small molecules, CD2 or LFA-3 mimetic agents, and derivatives therof.

Problems solved by technology

Presently known therapies for the above mentioned skin diseases are inadequate.
Most commonly encountered drawbacks for cyclosporin A include toxicity due to immunosuppression and renal and neural toxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
  • Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
  • Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction

Examples

Experimental program
Comparison scheme
Effect test

example 1

Subjects

[0111] Six adult patients participated in the investigation. Informed consent was obtained after Internal Review Board approval of the protocol. All patients satisfied the major diagnostic criteria for psoriasis, namely chronic papulosquamous plaques of characteristic morphology and distribution. -The intermittent use of topical corticosteroids was common among these patients but was discontinued 2 weeks prior to entry-into the study. A group of healthy volunteers with no history of psoriasis or other skin disease was utilized as the normal control group.

Preparation of Epidermal Cell Suspensions

[0112] Skin biopsy specimens were obtained from both normal and lesional skin by using a keratome. The specimens were submerged in Dulbecco's phosphate buffered saline (“PBS”); (Gibco Labs, Grand Island, N.Y.) containing 50 units / ml dispase (Collaborative Research, Bedford, Mass.). The specimens were then incubated at 4° C. for 18 hours and the epidermis removed from the remainin...

example 2

Subject

[0125] One adult subject participated in this investigation. Informed consent was obtained after Internal Review Board approval of the protocol. The minimal dose of UV B from a bank of fluorescent bulbs (FS 40) required to induce skin erythema in the subject was determined prior to the study. A moderate sunburn (4 minimal erythemal doses) was then administered to the left buttock, which 3 days later was the source of UV damaged skin. Skin from the right buttock, which was unburned, was utilized for the control.

Preparation of Epidermal Cell Suspensions

[0126] Skin biopsy specimens were obtained from both normal and sunburned skin by using a keratome. Epidermal cell suspensions were prepared from these specimens using substantially the same protocol as in Example 1.

Isolation and Deletion of T cells

[0127] Peripheral blood mononuclear cells (“MNC”) were isolated from heparinized blood of another person, using Ficoll-Hypaque® (Pharmacia) density gradient centrifugation acco...

example 3

Preparation of LFA3TIP

[0132] LFA3TIP, a fusion protein comprised of the first extracellular domain of LFA-3 fused to the hinge, CH2 and CH3 regions of human IgG1 was constructed as described in Miller, GT et al. (1993) J. Exp. Med.178:211, hereby incorporated by reference. LFA3TIP was purified from culture medium of transfectant CHO (chinese hamster ovary) cell lines by absorption to Protein-A Sepharose 4B® (Pharmacia) and eluted with 50 mM glycine, 250 mM NaCl (pH.3.0). Fractions containing protein were pooled and subjected to gel filtration on Superose-6 (Pharmacia) in phosphate buffered saline (PBS). Peak fractions were pooled and analyzed for purity on 12% reducing and non-reducing SDS-PAGE.

1. LFA3TIP Results in a Decrease of the Proliferative Response of Autologous Mononuclear Cells to Lesional Psoriatic Epidermal Cells

[0133] The ability of LFA3T1P to inhibit the response of autologous mononuclear cells (MNC) to lesional psoriatic epidermal cells (EC) in suspension was-det...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

Methods of using inhibitors of the CD2 / LFA-3 interaction-in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. Ser. No. 09 / 730,465, filed Dec. 5, 2000, which is a continuation of U.S. Ser. No. 08 / 466,465, filed Jun. 6, 1995, now U.S. Pat. No. 6,162,432, which is a continuation-in-part of U.S. Ser. No. 07 / 862,022, filed Apr. 2, 1992, now abandoned, and of PCT / US92 / 08755, filed Oct. 6, 1992, which is a continuation-in-part of U.S. Ser. No. 07 / 770,969, filed Oct. 7, 1991, now abandoned, all of which are herein incorporated by reference.TECHNICAL FIELD OF THE INVENTION [0002] This invention relates to methods of using inhibitors of the CD2 / LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C12Q1/68A61K38/00A61K39/00C07K14/705C07K16/28
CPCA61K38/00A61K2039/505C07K14/70507C07K14/70528C07K16/2806C07K16/2824C07K2316/96C07K2317/73C07K2319/30G01N33/57426G01N2333/70503G01N2333/70507G01N2500/00G01N2800/205Y10S514/885Y10S514/863C07K2317/76
Inventor WALLNER, BARBARACOOPER, KEVIN
Owner ASTELLAS US
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com